N-(2-methoxyphenyl)-2-(piperidin-1-yl)-5-[({2-[3-(prop-1-en-2-yl)phenyl]propan-2-yl}carbamoyl)amino]benzenesulfonamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N-(2-methoxyphenyl)-2-(piperidin-1-yl)-5-[({2-[3-(prop-1-en-2-yl)phenyl]propan-2-yl}carbamoyl)amino]benzenesulfonamide
• 英文别名: 1-[3-[(2-methoxyphenyl)sulfamoyl]-4-piperidin-1-ylphenyl]-3-[2-(3-prop-1-en-2-ylphenyl)propan-2-yl]urea
• 化学式: C₃₁H₃₈N₄O₄S
• 分子量: 562.7
• InChiKey: GUNQZZMJRXGITI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  40
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  108
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• [EN] THERAPEUTIC COMPOUNDS AND COMPOSITIONS<br/>[FR] COMPOSÉS ET COMPOSITIONS THÉRAPEUTIQUES
  申请人：AGIOS PHARMACEUTICALS INC

  公开号：WO2014062511A1

  公开（公告）日：2014-04-24

  Provided are aryl sulfonamide diarylurea derivative compounds that are inhibitors of mutant isocitrate dehydrogenase 1/2 (IDH 1/2), useful for treating cancer. Also provided are methods of treating cancer comprising administering to a subject in need thereof a compound described herein. Cancers that are treatable by the compounds of the invention are glioblastoma, myelodysplastic syndrome, myeloproliferative neoplasm, acute myelogenous leukemia, sarcoma, melanoma, non-small cell lung cancer, chondrosarcoma, and non-Hodgkin's lymphoma (NHL).

  提供的是芳基磺酰胺二芳基脲衍生物化合物，它们是突变异柠檬酸脱氢酶1/2（IDH 1/2）的抑制剂，可用于治疗癌症。还提供了治疗癌症的方法，包括向需要的受试者施用本文描述的化合物。本发明的化合物可用于治疗的癌症包括胶质母细胞瘤、骨髓增生异常综合征、骨髓增生性肿瘤、急性髓系白血病、肉瘤、黑色素瘤、非小细胞肺癌、软骨肉瘤和非霍奇金淋巴瘤（NHL）。
• THERAPEUTIC COMPOUNDS AND COMPOSITIONS
  申请人：AGIOS PHARMACEUTICALS, INC.

  公开号：US20150299115A1

  公开（公告）日：2015-10-22

  Provided are aryl sulfonamide diarylurea derivative compounds that are inhibitors of mutant isocitrate dehydrogenase 1/2 (IDH 1/2), useful for treating cancer. Also provided are methods of treating cancer comprising administering to a subject in need thereof a compound described herein. Cancers that are treatable by the compounds of the invention are glioblastoma, myelodysplastic syndrome, myeloproliferative neoplasm, acute myelogenous leukemia, sarcoma, melanoma, non-small cell lung cancer, chondrosarcoma, and non-Hodgkin's lymphoma (NHL).

  提供的是芳基磺酰胺二芳基脲衍生物化合物，它们是突变异柠檬酸脱氢酶1/2（IDH1/2）的抑制剂，用于治疗癌症。还提供了一种治疗癌症的方法，包括向需要治疗的受试者投与本文所述的化合物。本发明的化合物可治疗的癌症包括胶质母细胞瘤、骨髓增生异常综合征、骨髓增生性肿瘤、急性髓系白血病、肉瘤、黑色素瘤、非小细胞肺癌、软骨肉瘤和非霍奇金淋巴瘤（NHL）。
• Therapeutic compounds and compositions
  申请人：AGIOS PHARMACEUTICALS, INC.

  公开号：US10202339B2

  公开（公告）日：2019-02-12

  Provided are aryl sulfonamide diarylurea derivative compounds that are inhibitors of mutant isocitrate dehydrogenase 1/2 (IDH 1/2), useful for treating cancer. Also provided are methods of treating cancer comprising administering to a subject in need thereof a compound described herein. Cancers that are treatable by the compounds of the invention are glioblastoma, myelodysplastic syndrome, myeloproliferative neoplasm, acute myelogenous leukemia, sarcoma, melanoma, non-small cell lung cancer, chondrosarcoma, and non-Hodgkin's lymphoma (NHL).

  本发明提供的芳基磺酰胺二芳基脲衍生物化合物是突变型异柠檬酸脱氢酶 1/2（IDH 1/2）的抑制剂，可用于治疗癌症。还提供了治疗癌症的方法，包括向有需要的受试者施用本文所述的化合物。本发明化合物可治疗的癌症包括胶质母细胞瘤、骨髓增生异常综合征、骨髓增生性肿瘤、急性骨髓性白血病、肉瘤、黑色素瘤、非小细胞肺癌、软骨肉瘤和非霍奇金淋巴瘤（NHL）。